Skip to main content
Clinical Trials/NL-OMON54064
NL-OMON54064
Recruiting
Phase 2

Expression of prostate specific membrane antigen (PSMA) in soft tissue sarcomas and urothelial cell carcinomas: implications for tumour-specific molecular imaging and treatment? - PSMA expression & PSMA PET in soft tissue sarcoma/urothelial cell carcinoma

eids Universitair Medisch Centrum0 sites120 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
bladder cancer
Sponsor
eids Universitair Medisch Centrum
Enrollment
120
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years at the time of informed consent.
  • Diagnosis of advanced (locally irresectable or metastasized) soft tissue
  • sarcoma (cohort 1\) or advanced (muscle invasive or metastasized) urothelial
  • cell carcinoma (cohort 2\).
  • Voluntary agreement to provide written informed consent and the willingness and
  • ability to comply with all aspects of the protocol.
  • Recent (\< 8 weeks) standard imaging (with CT or \[18F]\-FDG PET/CT) with
  • measurable disease (lesion diameter \> 1 cm).
  • Biopsy available of primary tumour and/or metastasis
  • WHO performance status of 0\-2

Exclusion Criteria

  • Women who are pregnant and/or lactating.
  • Medical or psychiatric conditions that compromise the patient\*s ability to give
  • informed consent.
  • Known hypersensitivity to drugs comparative to \[18F]\-JK\-PSMA\-7, any of their
  • excipients or to any component of \[18F]\-JK\-PSMA\-7\.
  • Inability to undergo PET/CT scanning, e.g. claustrophobia, weight limits or
  • inability to tolerate lying down for the duration of a PET/CT scan (\~30

Outcomes

Primary Outcomes

Not specified

Similar Trials